|
|
|
|
 |
|
International Stem Cell Corporation Announces Manufacturing and Supply Agreement With ATCC |
| 3/31/2008 @ 6:52 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
International Stem Cell Corporation (OTCBB:ISCO) announced today that it has entered into an agreement with ATCC (American Type Culture Collection, Manassas, Va.) To manufacture living primary cells and cell culture products for worldwide distribution by ATCC into the biological research market.
“We are proud of our relationship with ATCC. They are well known around the world as a leader in supplying biomaterials for critical research being conducted in the field of life sciences,” according to Jeffrey Janus, President of ISCO. “Relationships with quality organizations such as ATCC are critical to ISCO’s future success. This is yet another important step toward ISCO’s becoming the industry leader in providing cells and cell products for therapy. We advance our therapeutic goals by generating revenue, scientific knowledge and infrastructure through research, product manufacture and sales.”
International Stem Cell Corporation is the first company to perfect a method of creating human stem cells from unfertilized eggs. These cells, called “parthenogenetic” stem cells alleviate two critical problems inherent in cell transplantation today — immune rejection and the ethical issues associated with the use of fertilized human embryos — yet they retain the ability to differentiate into all tissue types.
“These products and the expertise of ISCO broaden the ATCC offering and complement our strong position in cell biology,” said Michael Gove, ATCC VP for Marketing and Sales. “Offering primary cells and culture products will enhance our position as the world’s leading biological resource center and provide our customers more high-quality reagents for their research.”
ATCC, a global nonprofit, supports biological research by acquiring, authenticating, developing, preserving and distributing the world’s most comprehensive source of cell and microbial reference cultures and reagents. ATCC functions as a biological repository, a research organization and a service provider for use by researchers in academic and industry laboratories.
ISCO, through its wholly owned subsidiary, Lifeline Cell Technology (Walkersville, MD) develops and manufactures optimized human cell culture products for research use. These products consist of frozen cells and cell culture media and reagents and include stem cell products.
About ATCC:
ATCC is the world’s largest biological resource center and the most comprehensive source of reference cultures and reagents used by researchers in academic and industry laboratories. Since 1925, ATCC, also known as American Type Culture Collection, has set the standard for authentication and distribution of biological reference materials for life science research in the public and private sector. Www.atcc.org.
About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation (ISCO) is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true “Stem Cell Bank” and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, August 28, 2008 |
 |
|
Orexigen Therapeutics to Present at Upcoming Investor Conferences Posted 3:16 PM PST
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences Posted 3:15 PM PST
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference Posted 3:14 PM PST
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Posted 3:13 PM PST
Volcano Presentation at Thomas Weisel Conference to Be Webcast Posted 3:12 PM PST
Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008 Posted 3:12 PM PST
Illumina to Present at Upcoming Investment Conferences in September Posted 7:43 AM PST
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference Posted 7:42 AM PST
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008 Posted 7:42 AM PST
|
| |
| Wednesday, August 27, 2008 |
|
|
Genoptix Announces Participation at the 2008 Southern California Investor Conference Posted 9:08 AM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA Posted 3:42 PM PST
Cyntellect to Collaborate With the Burnham Institute for Medical Research; In situ live cell manipulation on LEAP to empower purification of stem cells and their differentiated progeny Posted 8:57 AM PST
TorreyPines Therapeutics Receives NASDAQ Deficiency Notice Posted 8:50 AM PST
JMAR Technologies Awarded Development Contract by the Johns Hopkins University Applied Physics Laboratory Posted 8:29 AM PST
Aperio Receives FDA Clearance for ER and PR Image Analysis Applications Posted 7:52 AM PST
|
| |
| Monday, August 25, 2008 |
|
|
Amylin and Lilly Set Date and Time for Conference Call; Companies Will Discuss Recent FDA Advisory Regarding BYETTA Posted 4:17 PM PST
Cripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer Posted 4:13 PM PST
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference Posted 4:12 PM PST
Invitrogen Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger with Applied Biosystems Posted 6:15 AM PST
|
| |
| Friday, August 22, 2008 |
|
|
ALISO VIEJO--- Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference Posted 6:20 AM PST
|
| |
| Thursday, August 21, 2008 |
|
|
Moores UCSD Cancer Center Luau & Longboard Invitational Celebrates 15 Years of 'Surfing For A Cure' on August 24 Posted 4:14 PM PST
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial Posted 4:13 PM PST
Patent Issued Related to Prometheus Proprietary Test Cbir1 Antigen Test Included in Diagnostic for Inflammatory Bowel Disease Posted 4:12 PM PST
Vaxfectin -formulated Measles DNA Vaccine Could Address Unmet Need for Infants Posted 4:11 PM PST
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients Posted 4:03 PM PST
|
| |
| Tuesday, August 19, 2008 |
|
|
Karolinska Institute to Test Vical's Vaxfectin Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control Posted 7:59 AM PST
Invitrogen Launches Legionella Test to Streamline Surveillance Posted 7:29 AM PST
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors Posted 7:26 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
